CONSENSUS STATEMENT: THE POSITION OF THE HEADACHE SECTION OF THE HELLENIC SOCIETY OF NEUROLOGY ON THE INCORPORATION OF MONOCLONAL ANTIBODIES FOR THE PREVENTION OF MIGRAINE IN CLINICAL PRACTICE IN GREECE

Abstract

Three monoclonal antibodies against CGRP or its receptor have already been approved for use in the prophylactic treatment of migraine in the European Union and, hence, in Greece. Current indication for all of them includes prevention of migraine in patients with 4 or more migraine days per month. In order to facilitate the smooth integration of these new medications into the clinical practice of the Greek neurologists, as well as considering the limitations of public health resources, the Headache Section of the Hellenic Neurological Society decided to create the present consensus paper, which also integrates the views of Greek patients with migraine, as well as the relevant recommendations of the American Headache Society and those of the European Headache Federation, that were created in a similar way and rationale, all adapted to the standards of Greece. In the first part, a brief reference is made to the clinical data, while in the second part, consensual clinical guidance is provided, in the form of recommendations based on clinical criteria, on the decisions regarding the initiation, evaluation and discontinuation of these therapies. The current recommendations should be re-evaluated in no more than one year.